Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints—a cohort study

Figures & data

Table 1. Patient characteristics.

Parameter	Overall n (%)/median (range)	Sanz low risk n (%)/median (range)	Sanz high risk n (%)/median (range)	p-Value
N	64	32	32
Age (years)	28 (5–60)	27.5 (7–60)	28.5 (5–57)	0.866
Gender				0.309
Male	26 (40.6)	11 (34.4)	15 (46.9)
Female	38 (59.4)	21 (65.6)	17 (53.1)
Duration of symptoms (days)	30 (3–365)	30 (7–365)	15 (3–90)	0.002
TLC (/μL)	9000 (220–250,000)	2310 (220–7500)	23,000 (10,500–250,000)	0.0001
Haemoglobin (g/dl)	7.3 (1.9–10.8)	7.1 (4.5–10.2)	7.6 (1.9–10.8)	0.542
Platelet (/μL)	19,000 (3000–130,000)	185,000 (4000–130,000)	195,000 (3000–100,000)	0.513
DIC	52 (81.25)	22 (68.8)	30 (93.8)	0.022
Baseline infection	35 (57.4)	19 (59.4)	16 (55.2)	0.74
Therapy received				0.0001
ATRA + Daunorubicin + ATO	11 (17.19)	0 (0)	11(34.3)
ATRA + Daunorubicin	10 (15.62)	4 (12.5)	6 (18.8)
ATRA + ATO	38 (59.38)	26 (81.25)	13 (40.6)
Others	5 (7.81)	2 (6.25)	2 (6.3)
Infection on Rx	40 (62.5)	16 (50)	24 (75)	0.039
Incidence of DS	36 (56.25)	14 (43.8)	22 (68.8)	0.044
Severity of DS				0.407
Moderate	10 (27.8)	5 (35.7)	5 (22.7)
Severe	26 (72.2)	9 (64.3)	17 (77.3)
Day of DS development	4 (0–14)	5 (2–14)	3 (0–13)	0.074
ATRA desquamation	9 (14.06)	3 (9.38)	6 (14.06)	0.474
Pseudotumor cerebri	11 (17.2)	7 (21.8)	4 (12.5)	0.509
Induction outcomes				0.148
CR	48 (75)	27 (84.4)	21 (65.6)
Death	16 (25)	5 (15.6)	11 (34.4)

Figure 1. Kaplan Meier survival analysis curve to compare event free survival between low and high-risk APL.

Figure 2. Kaplan Meier survival analysis curve to compare overall survival between low and high-risk APL.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author, MA. The data are not publicly available because it could compromise the privacy of research participants.